Dyno Therapeutics and Roche have announced a second research collaboration to develop adeno-associated virus (AAV) vectors for gene therapies targeting neurological diseases. Dyno and Roche previously agreed a research collaboration and license agreement for neurological diseases and liver-directed therapies in October 2020. Under the terms of this new collaboration, Dyno Therapeutics provides Roche further access […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!